Related Experiment Videos
Inhibition of adrenergic vasoconstriction by quinidine
The Journal of Pharmacology and Experimental Therapeutics
|January 1, 1974
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A leptin-sympathetic-leptin feedback loop: potential implications for regulation of arterial pressure and body fat.
Acta physiologica Scandinavica·2003
Clinician scientist training program: a proposal for training medical students in clinical research.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2001
Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation?
Hypertension (Dallas, Tex. : 1979)·2001
Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure.
Hypertension (Dallas, Tex. : 1979)·2001
Does leptin cause functional peripheral sympatholysis?
American journal of hypertension·2001
Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure.
Hypertension (Dallas, Tex. : 1979)·2001
Repurposing ribavirin for oncology: Integrating metabolism, signaling, and translational control.
The Journal of pharmacology and experimental therapeutics·2026
Circular RNAs regulate the progression of pulmonary hypertension through distinct roles and mechanisms.
The Journal of pharmacology and experimental therapeutics·2026
US postmarketed drug removals: Analysis of discontinued and withdrawn drugs.
The Journal of pharmacology and experimental therapeutics·2026
RRx-001 sensitizes triple-negative breast cancer cells to oxaliplatin through apoptosis, cell cycle arrest, and immune modulation.
The Journal of pharmacology and experimental therapeutics·2026
Dynamic mechanistic dominance in fentanyl and polysubstance overdose: Implications for next-generation reversal.
The Journal of pharmacology and experimental therapeutics·2026
Risk of liver adverse events with nivolumab/ipilimumab combination therapy for hepatocellular carcinoma: A disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System data base.
The Journal of pharmacology and experimental therapeutics·2026